Biological activities and mechanisms of action of PGJ2 and related compounds: an update.
Fukushima
M
M
Department of Internal Medicine, Aichi Cancer Center, Nagoya, Japan.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D006358:Hot Temperature / Q000009:adverse effects; D006801:Humans; D007249:Inflammation / Q000209:etiology; D015394:Molecular Structure; D009363:Neoplasm Proteins; D010012:Osteogenesis / Q000187:drug effects; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000502:physiology; D025521:Tumor Suppressor Proteins
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D002352:Carrier Proteins; C107608:FABP7 protein, human; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D009363:Neoplasm Proteins; D025521:Tumor Suppressor Proteins; C037112:9-deoxy-delta-9-prostaglandin D2; D015230:Prostaglandin D2